In our study, we used post/pre-treatment CEA ratio as a new index to estimate the change of CEA during neoadjuvant treatment and it was suggested that lower CEA ratio was an independent predictor for favor tumor regression in terms of TRG 0/1 and tumor downstage. The gene discussed is CEACAM5; the disease is neoplasm.